Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
When do you recommend adjuvant trastuzumab for completely resected uterine cancer and for how long do you give it?
Related Questions
What are your top takeaways in Gyn Cancers from ASCO 2025?
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
Are there patient populations in whom you would consider using both induction chemotherapy and maintenance pembrolizumab for a patient with locally advanced cervical cancer?
For an elderly woman with a platinum-resistant recurrence of a high-grade serous ovarian cancer who has been rendered NED surgically, is observation a reasonable approach?
What is your experience with in vitro chemosensitivity testing?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
For a patient with locally current endometrial cancer whose disease had complete radiographic response to carboplatin, Taxol, and pembrolizumab, would you consider adding radiation therapy?
Would you offer systemic chemotherapy to a patient with at least 2023 FIGO stage IC high grade serous (p53-mut) endometrial cancer with extensive LVI for whom nodal assessment was not done?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
Would you consider adding immunotherapy to adjuvant chemotherapy in a patient with incompletely staged, high-grade, MSI-H, POLE-mutated endometrioid carcinoma of the ovary with ultra-high tumor mutation burden on NGS?
